CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

… underlying genetic causes of human disease. CTX001 represents the … has deep insight into causal human biology, including pain, … offices in North America, Europe, Australia and Latin America. … LGBTQ equality by the Human Rights Campaign. For company updates …

The post CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition first appeared on TheEuropeanTimes.INFO.